SOPHiA GENETICS (NASDAQ: SOPH) CMO sells 5,100 shares under 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported routine share sales tied to equity compensation taxes. He sold a total of 5,100 Ordinary Shares in open-market transactions on April 6 and 7, 2026 at weighted average prices of $4.8505 and $4.8653 per share.

According to the disclosure, these sales were made to satisfy tax withholding obligations arising from restricted stock unit vesting on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, rather than as discretionary trades. Following the sales, he directly holds 281,452 Ordinary Shares.

Insights

Equity compensation analyst

Routine, pre-planned tax-driven sales with substantial holdings retained.

Chief Medical Officer Philippe Menu sold 5,100 Ordinary Shares of SOPHiA GENETICS SA in two open-market transactions at weighted average prices of $4.8505 and $4.8653. The filing states these sales were to cover tax withholding from restricted stock unit vesting.

The footnotes clarify that all transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily. After these sales, Menu still owns 281,452 Ordinary Shares directly, so the disposals represent a small portion of his visible position.

Insider Trade Summary 10b5-1

Net Seller: 5,100 shares ($24,773)

Net Sell 2 txns

Insider Menu Philippe

Role Chief Medical Officer

Sold 5,100 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,400	$4.8653	$12K
Sale	Ordinary Shares	2,700	$4.8505	$13K

Holdings After Transaction: Ordinary Shares — 281,452 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.62 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $4.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold April 6, 2026: 2,700 shares Shares sold April 7, 2026: 2,400 shares Total shares sold: 5,100 shares +4 more

7 metrics

Shares sold April 6, 2026 2,700 shares Open-market sale of Ordinary Shares at weighted average $4.8505

Shares sold April 7, 2026 2,400 shares Open-market sale of Ordinary Shares at weighted average $4.8653

Total shares sold 5,100 shares Combined tax-withholding sales over April 6–7, 2026

Weighted average price April 6 $4.8505 per share Multiple transactions between $4.78 and $4.98

Weighted average price April 7 $4.8653 per share Multiple transactions between $4.62 and $4.95

Holdings after April 7 sale 281,452 shares Direct ownership of Ordinary Shares following reported transactions

Holdings after April 6 sale 283,852 shares Direct ownership immediately after April 6 transaction

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average price

3 terms

Rule 10b5-1 trading plan financial

"These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/06/2026		S		2,700(1)	D	$4.8505	283,852(2)	D
Ordinary Shares	04/07/2026		S		2,400(1)	D	$4.8653	281,452(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.62 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $4.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) CMO Philippe Menu report in this Form 4?

He reported selling 5,100 Ordinary Shares of SOPHiA GENETICS SA in open-market transactions. The sales occurred on April 6 and 7, 2026 at weighted average prices of $4.8505 and $4.8653 per share, and were disclosed as part of his equity compensation activity.

Why did the SOPH CMO sell shares, according to the Form 4 footnotes?

The filing states the shares were sold to satisfy tax withholding obligations from restricted stock unit vesting on April 2 and 3, 2026. This frames the activity as compensation-related and tax-driven rather than a discretionary decision to reduce his overall investment in the company.

How many SOPHiA GENETICS shares does the CMO hold after these transactions?

After the reported transactions, Chief Medical Officer Philippe Menu directly owns 281,452 Ordinary Shares. This indicates that the 5,100 shares sold for tax withholding purposes represent only a small fraction of his total disclosed direct holdings in SOPHiA GENETICS SA.

Were the SOPH insider share sales made under a Rule 10b5-1 plan?

Yes. The footnotes specify that the sales were executed under a pre-established Rule 10b5-1 trading plan. Such plans are set up in advance to systematically sell shares, helping separate routine liquidity or tax events from discretionary market-timed trading decisions by insiders.

What price range did the SOPH CMO’s Form 4 disclose for the share sales?

The Form 4 reports weighted average prices of $4.8505 and $4.8653 per share. Footnotes note that individual trades occurred within ranges of $4.62–$4.95 and $4.78–$4.98, respectively, and the insider offers to provide detailed trade-by-trade pricing information upon written request.

How many SOPHiA GENETICS shares did the CMO sell on each transaction date?

He sold 2,700 Ordinary Shares on April 6, 2026 at a weighted average price of $4.8505 per share, and 2,400 Ordinary Shares on April 7, 2026 at a weighted average price of $4.8653 per share. Together, these tax-related sales total 5,100 shares.